BACKGROUND: There is a pressing need for new forms of treatment for COPD. Based on the known pathophysiology of COPD, inhibition of matrix metalloproteinases is a theoretically promising approach. This Phase IIa study evaluated the effects of AZD1236, a selective MMP-9 and MMP-12 inhibitor, on the biomarkers of inflammation and emphysematous lung tissue degradation in patients with moderate-to-severe COPD. METHODS: This was a multinational, randomized, double-blind, placebo-controlled signal-searching study conducted in men and women aged ≥40 years with stable moderate-to-severe COPD. After a 2-6-week period to eliminate any remaining effects of previous medication, 55 patients received oral AZD1236 75 mg or matching placebo twice daily for 6 weeks. Differential cell count and TNF-α levels in induced sputum and 24-h urinary desmosine excretion were the main study variables, but a range of exploratory biomarkers was also assessed in induced sputum, blood and urine. Secondary variables included lung function and patient-recorded Clinical COPD Questionnaire (CCQ) responses and diary records of symptoms, adverse events, use of rescue medication and AZD1236 plasma concentrations. RESULTS: The majority of variables showed little change compared to placebo although there was a possible, but not statistically significant reduction in urinary desmosine excretion and reductions in the number and percentage of lymphocytes in sputum and blood with AZD1236. No effect was seen on clinical parameters after 6 weeks of treatment. The proportion of patients experiencing adverse events was similar in both treatment groups. CONCLUSIONS:AZD1236 dosed orally at 75 mg twice daily was generally well tolerated over 6 weeks in patients with moderate-to-severe COPD. No clinical efficacy of AZD1236 was demonstrated in this short-term signal-searching study, although possible evidence of an impact on desmosine may suggest the potential value of selective inhibitors of MMPs in the treatment of COPD in longer term trials. Copyright Â
RCT Entities:
BACKGROUND: There is a pressing need for new forms of treatment for COPD. Based on the known pathophysiology of COPD, inhibition of matrix metalloproteinases is a theoretically promising approach. This Phase IIa study evaluated the effects of AZD1236, a selective MMP-9 and MMP-12 inhibitor, on the biomarkers of inflammation and emphysematous lung tissue degradation in patients with moderate-to-severe COPD. METHODS: This was a multinational, randomized, double-blind, placebo-controlled signal-searching study conducted in men and women aged ≥40 years with stable moderate-to-severe COPD. After a 2-6-week period to eliminate any remaining effects of previous medication, 55 patients received oral AZD1236 75 mg or matching placebo twice daily for 6 weeks. Differential cell count and TNF-α levels in induced sputum and 24-h urinary desmosine excretion were the main study variables, but a range of exploratory biomarkers was also assessed in induced sputum, blood and urine. Secondary variables included lung function and patient-recorded Clinical COPD Questionnaire (CCQ) responses and diary records of symptoms, adverse events, use of rescue medication and AZD1236 plasma concentrations. RESULTS: The majority of variables showed little change compared to placebo although there was a possible, but not statistically significant reduction in urinary desmosine excretion and reductions in the number and percentage of lymphocytes in sputum and blood with AZD1236. No effect was seen on clinical parameters after 6 weeks of treatment. The proportion of patients experiencing adverse events was similar in both treatment groups. CONCLUSIONS:AZD1236 dosed orally at 75 mg twice daily was generally well tolerated over 6 weeks in patients with moderate-to-severe COPD. No clinical efficacy of AZD1236 was demonstrated in this short-term signal-searching study, although possible evidence of an impact on desmosine may suggest the potential value of selective inhibitors of MMPs in the treatment of COPD in longer term trials. Copyright Â
Authors: Sara Ongay; Marijke Sikma; Peter Horvatovich; Jos Hermans; Bruce E Miller; Nick H T Ten Hacken; Rainer Bischoff Journal: Chronic Obstr Pulm Dis Date: 2016-03-01
Authors: Carlo Baggio; Linda Cerofolini; Marco Fragai; Claudio Luchinat; Maurizio Pellecchia Journal: ACS Med Chem Lett Date: 2018-01-17 Impact factor: 4.345
Authors: Irene M J Eurlings; Mieke A Dentener; Evi M Mercken; Rafael de Cabo; Ken R Bracke; Juanita H J Vernooy; Emiel F M Wouters; Niki L Reynaert Journal: Am J Physiol Lung Cell Mol Physiol Date: 2014-08-08 Impact factor: 5.464
Authors: Benjamin B Sun; Joseph C Maranville; James E Peters; David Stacey; James R Staley; James Blackshaw; Stephen Burgess; Tao Jiang; Ellie Paige; Praveen Surendran; Clare Oliver-Williams; Mihir A Kamat; Bram P Prins; Sheri K Wilcox; Erik S Zimmerman; An Chi; Narinder Bansal; Sarah L Spain; Angela M Wood; Nicholas W Morrell; John R Bradley; Nebojsa Janjic; David J Roberts; Willem H Ouwehand; John A Todd; Nicole Soranzo; Karsten Suhre; Dirk S Paul; Caroline S Fox; Robert M Plenge; John Danesh; Heiko Runz; Adam S Butterworth Journal: Nature Date: 2018-06-06 Impact factor: 49.962
Authors: Michael C McKelvey; Ryan Brown; Sinéad Ryan; Marcus A Mall; Sinéad Weldon; Clifford C Taggart Journal: Int J Mol Sci Date: 2021-05-09 Impact factor: 5.923